3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
9
Recruiting
4
Withdrawn
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
848
Triple Negative Breast Neoplasms
136
Ovarian Neoplasms
55
Colorectal Neoplasms
49
Carcinoma, Non-Small-Cell Lung
47
Neoplasms
43
Prostatic Neoplasms
42
Neoplasm Metastasis
42
Lung Neoplasms
38
Melanoma
30
Carcinoma, Intraductal, Noninfiltrating
29
Uterine Cervical Neoplasms
27
Pancreatic Neoplasms
25
Colonic Neoplasms
25
Stomach Neoplasms
23
Squamous Cell Carcinoma of Head and Neck
23
Endometrial Neoplasms
23
Carcinoma, Renal Cell
23
Breast Carcinoma In Situ
22
Esophageal Neoplasms
17
Urinary Bladder Neoplasms
16
Motor Activity
16
Inflammatory Breast Neoplasms
16
Head and Neck Neoplasms
16
Small Cell Lung Carcinoma
15
Sarcoma
14
Breast Cancer Female
13
Brain Neoplasms
12
Anatomic Stage I Breast Cancer AJCC v8
12
Gastrointestinal Neoplasms
11
Interventions
capivasertib
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Disease Progression
×
Breast
×
Clear all
NCT06635447
2026-03-27
CAPItrue
AstraZeneca
Phase 3
Active not recruiting
258 enrolled